Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Call for proposals
TPPs & TCPs
Learning resources for discovery scientists
Project of the year award
Computational chemistry
Global health compound design webinars
R&D challenges
Access
Products & projects
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Product maps
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
The road to health impact
Access challenges
Partnering
Our partner network
The PDP model
Socially responsible agreements
Our clinical centre partners
Our donors
Current donors
Past donors
Donate to MMV
Our impact
Achievements
Real life stories
Better medicines for children
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff map
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
MMV's internship programme
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Optimizing artemisinin production
Malaria online course
Newsroom
News & Press Releases
Audio
Media interviews
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
COVID Box
About the COVID Box
Request the COVID box
Supporting information
COVID Box terms and conditions
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
Pathogen Box
About the Pathogen Box
Exploiting the Pathogen Box
Pathogen Box research
Supporting information
Terms & conditions
Malaria Box
About the Malaria Box
Malaria Box Research
Supporting information
Terms & conditions
Map of box orders
Follow-up guidelines
Open Source Drug Discovery
MMV Open Team
Contact us
Home
Newsroom
News & Press Releases
News & Press Releases
Filter
Category
All
News story
Press release
Topic
Access & product management
Donors
General
Open source
Partner
R&D
Search Terms
430 found
Position paper and presentations: Exploring combinations of antimalarial drugs meeting
19 Mar 2008
Dacart development halted based on Phase III results
29 Feb 2008
MMV and other PPPs encourage additional US Government support
11 Jan 2008
MMV features in The Pulse on Al Jazeera
04 Jan 2008
MoH - MMV: Bold intervention being designed in Uganda to deliver subsidized effective antimalarials
01 Oct 2007
DHA Piperaquine wins Good Clinical Practice Journal (GCPj) Award
06 Sep 2007
US NIH grants MMV over USD 5 mn for malaria research
06 Sep 2007
Start of Phase II trial of intravenous artesunate for children with severe malaria
29 Aug 2007
Orphan Drug Status for MMV Drug DHA-Piperaquine
25 Jul 2007
World Bank Reviews MMV’s Growth and Progress
18 Jul 2007
MMV Project of the Year goes to Next Generation OZ
14 May 2007
New malaria clinical trial site inaugurated at Bagamoyo, Tanzania
10 May 2007
Dr Chris Hentschel interviewed in Kampala by AllAfrica.org
09 May 2007
Uganda and MMV explore innovative ways to give patients access to life-saving antimalarials
09 May 2007
Africa Malaria Day - A Malaria Community Statement
25 Apr 2007
Partnerships hold the key
25 Apr 2007
DNDi launches a fixed-dose ACT
02 Mar 2007
Work of MMV highlighted at World Economic Forum Annual Meeting
31 Jan 2007
Pivotal clinical trials launched for new artemisinin-based malaria drug combination
25 Jan 2007
Malaria Map: New Tool for Malaria Control
06 Dec 2006
Dutch government pledges nearly €7 million to MMV
03 Nov 2006
Medicines for Malaria Venture, Higher Colleges of Technology and Global Medical Forum Foundation Collaborate on Innovative Abu Dhabi Bio City Research Initiative to Tackle Malaria
18 Oct 2006
MMV announces a commitment of US$50 million to advance malaria research at President Clinton’s Global Initiative
21 Sep 2006
Pivotal Studies Begin for CDA in sub-Saharan Africa
25 Jul 2006
Project to jump-start efficacy of Artemisia Annua
22 Jun 2006
MMV calls for action against counterfeit drugs
06 Jun 2006
Novartis spearheads innovative malaria research project in newly created public-private partnership
23 May 2006
Irish Aid announces a grant to MMV of €9 million over the next three years
11 May 2006
MMV Stakeholders’ Meeting - Shin Poong Pharm. wins Project of the Year
06 May 2006
New Alliance to Build African Capacity for Malaria Drug and Vaccine Research
24 Apr 2006
MMV applauds WHO’s call to halt malaria monotherapy
23 Jan 2006
University of Mississippi, MMV, and DNDi to collaborate on development of anti-parasitic drugs
14 Dec 2005
RBx11160 demonstrates significant parasite reduction in patients
13 Dec 2005
MMV swims 10 km in World Swim for Malaria
03 Dec 2005
New ACT confirms potential use against malaria
13 Nov 2005
Gates Foundation commits $258.3 mn for malaria R&D with $100 mn for MMV
31 Oct 2005
Landmark study: malaria gets less than 1% of global health R&D investment
30 Oct 2005
DfID and the Wellcome Trust announce new grant for MMV
29 Oct 2005
Dihydroartemisinin and Piperaquine could become a major weapon against malaria
03 Oct 2005
Pyronaridine-Artesunate (PANDA)
15 Aug 2005
Open Letter to Leaders of the G-8 Nations
17 Jun 2005
GlaxoSmithKline and University of California, San Francisco win Medicines for Malaria Venture’s Project of the Year 2004 Award
29 May 2005
MMV and GlaxoSmithKline collaborate to fight malaria
11 Nov 2004
USAID announces $16 million for new malaria initiatives, $8 million for MMV
27 Oct 2004
Nature publishes research paper, Identification of an antimalarial synthetic trioxolane drug development candidate
19 Aug 2004
BHP Billiton joins Medicines for Malaria Venture in the fight against malaria
02 Jun 2004
GlaxoSmithKline wins Medicines for Malaria Venture’s Project of the Year Award 2003
01 Jun 2004
GlaxoSmithKline, WHO/TDR and the Medicines for Malaria Venture collaborate to fight malaria
23 Apr 2004
Chongqing Holley, Sigma Tau, Medicines for Malaria Venture and University of Oxford sign historic partnership agreement to develop antimalarial drug
19 Mar 2004
University of Mississippi and Medicines for Malaria Venture Explore New Drug Compound for Treatment of Malaria
02 Mar 2004
Paratek Pharmaceuticals and Medicines for Malaria Venture collaborate to discover novel antimalarial compounds
24 Feb 2004
Dr Pascoal Mocumbi, named High Representative of the European and Developing Countries Clinical Trials Partnership (EDTCP) by the European Commission
19 Jan 2004
Medicines for Malaria Venture, Immtech and University of North Carolina at Chapel Hill sign agreement to develop a new treatment for malaria
03 Dec 2003
Medicines for Malaria Venture and Novartis agree to develop a pediatric formulation of Coartem®
10 Nov 2003
Dr Pascoal Manuel Mocumbi, Prime Minister of Mozambique, joins MMV Board
13 Oct 2003
The Bill & Melinda Gates Foundation commits $168 million to accelerate malaria research
21 Sep 2003
Pfizer reports important research developments against malaria
26 Jun 2003
Medicines for Malaria Venture and GlaxoSmithKline (GSK) team up to fight malaria in developing countries
13 Jun 2003
Roche hands over to Ranbaxy
18 May 2003
All press clippings from MMV’s 3rd Annual Stakeholders’ Meeting
18 May 2003
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »